# Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients

> **NCT00497796** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 307 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **DRUG:** maribavir
- **DRUG:** ganciclovir

## Key facts

- **NCT ID:** NCT00497796
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-23
- **Primary completion:** 2009-09-14
- **Final completion:** 2009-09-14
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00497796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00497796, "Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00497796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*